Mike Pishvaian
@MPishvaian
GI Onc at Hopkins, focusing on #PancreaticCancer, #PrecisionMedicine. Striving to improve patient outcomes.
Originator of #TumorBoardTuesday @TumorBoardTues
ID:1053997767855611904
21-10-2018 13:13:44
11,7K Tweets
4,2K Followers
1,0K Following
Follow People
In this review, Dr. Hari K. Koul's team discussed the genetics of pancreatic cancer and its role in tumor evolution and treatment resistance
Pylayeva-Gupta lab Wungki Park, MD MS Cullen Taniguchi, MD Mike Pishvaian Diane M. Simeone, MD Howard Crawford Rushika M. Perera Bryant Lab UNC Derk Klatte Brady Campbell, MD MPH
Matt Galsky Mike Pishvaian Jon Anker, MD, PhD #TumorBoardTuesday Amanda Nizam, MD Brian Rini, MD Petros Grivas Nick James Toni Choueiri, MD Rana McKay Rafee Talukder Shilpa Gupta Adam Weiner Adam Kibel aurelius omlin Arnab Basu Arvin K. George, MD Arun Azad π³ππππ π²ππππ Ciara Conduit Dana-Farber Lank Center for Genitourinary Oncology Dan George Ali Khaki Mike Glover Daniel Petrylak D'Ann George Deborah Mukherji DrTylerStewart Emmanuel Antonarakis EAU Edu Platform UROONCO Elena Castro Edward Schaeffer Eric Jonasch Tamas Fazekas MD Jean Hoffman-Censits Brian Shuch, MD Miguel Sotelo Santhosh Ambika Russell Pachynski Scot Niglio MD Alfonso GΓ³mez de LiaΓ±o Sam S. Chang MD, MBA Joseph Vento Tom Powles drfrankiejs Katy Beckermann Albert Jang, MD Yu-Wei Chen, MD, MS Christopher Hoimes Jonathan Rosenberg MD Using monotherapy data from KEYNOTE-045 and EV-103 (cohort K) ,
Enfortumab-vedotin + Pembrolizumab in EV-302 is precisely as effective as expected by additivity
Shows again that additive combos of highly active agents are the biggest wins & predictably so
nature.com/articles/s4301β¦
David k. Calsina Quispe Hannah/ Heather Hannon, DNP Mike Pishvaian Jon Anker, MD, PhD #TumorBoardTuesday Matt Galsky Amanda Nizam, MD Brian Rini, MD Petros Grivas Nick James Toni Choueiri, MD Rana McKay Rafee Talukder Shilpa Gupta Adam Weiner Adam Kibel aurelius omlin Arnab Basu Arvin K. George, MD Arun Azad π³ππππ π²ππππ Ciara Conduit Dana-Farber Lank Center for Genitourinary Oncology Dan George Ali Khaki Mike Glover Daniel Petrylak D'Ann George Deborah Mukherji DrTylerStewart Emmanuel Antonarakis EAU Edu Platform UROONCO Elena Castro Edward Schaeffer Eric Jonasch Tamas Fazekas MD Jean Hoffman-Censits Brian Shuch, MD Miguel Sotelo Santhosh Ambika Russell Pachynski Scot Niglio MD Alfonso GΓ³mez de LiaΓ±o Sam S. Chang MD, MBA Joseph Vento Tom Powles drfrankiejs Katy Beckermann Great question- Iβm not sure. Any insights here Jon Anker, MD, PhD & Matt Galsky?
#TumorBoardTuesday Matt Galsky Amanda Nizam, MD Brian Rini, MD Petros Grivas Nick James Toni Choueiri, MD Rana McKay Rafee Talukder Shilpa Gupta Adam Weiner Adam Kibel aurelius omlin Arnab Basu Arvin K. George, MD Arun Azad π³ππππ π²ππππ Ciara Conduit Dana-Farber Lank Center for Genitourinary Oncology Dan George Ali Khaki Mike Glover Daniel Petrylak D'Ann George Deborah Mukherji DrTylerStewart Emmanuel Antonarakis EAU Edu Platform UROONCO Elena Castro Edward Schaeffer Eric Jonasch Tamas Fazekas MD Jean Hoffman-Censits Brian Shuch, MD Miguel Sotelo Santhosh Ambika Russell Pachynski Scot Niglio MD Alfonso GΓ³mez de LiaΓ±o Sam S. Chang MD, MBA Joseph Vento Tom Powles drfrankiejs Katy Beckermann Albert Jang, MD Michiel van der Heijden Guru P. Sonpavde, MD Andrea Necchi #PostTest Q2οΈβ£ #TumorBoardTuesday
ππ½ Free CME π integrityce.com/TBT2023
π€Which treatment was received by the majority of patients in EV-302 who needed subsequent therapy after treatment w/ enfortumab vedotin + pembrolizumabβ
#TumorBoardTuesday Matt Galsky Amanda Nizam, MD Brian Rini, MD Petros Grivas Nick James Toni Choueiri, MD Rana McKay Rafee Talukder Shilpa Gupta Adam Weiner Adam Kibel aurelius omlin Arnab Basu Arvin K. George, MD Arun Azad π³ππππ π²ππππ Ciara Conduit Dana-Farber Lank Center for Genitourinary Oncology Dan George Ali Khaki Mike Glover Daniel Petrylak D'Ann George Deborah Mukherji DrTylerStewart Emmanuel Antonarakis EAU Edu Platform UROONCO Elena Castro Edward Schaeffer Eric Jonasch Tamas Fazekas MD Jean Hoffman-Censits Brian Shuch, MD Miguel Sotelo Santhosh Ambika Russell Pachynski Scot Niglio MD Alfonso GΓ³mez de LiaΓ±o Sam S. Chang MD, MBA Joseph Vento Tom Powles drfrankiejs Katy Beckermann Albert Jang, MD Michiel van der Heijden Guru P. Sonpavde, MD Andrea Necchi #PostTest Q1οΈβ£ #TumorBoardTuesday
ππ½ #CME Eval π integrityce.com/TBTeval23
ππ½ALL CMEπ integrityce.com/TBT2023
π€What 1L Tx would you give to a 68yoβοΈw/ mUC, PS 1, & new SOB after 1y after gem/cis & cystectomyβ
#TumorBoardTuesday Matt Galsky Amanda Nizam, MD Brian Rini, MD Petros Grivas Nick James Toni Choueiri, MD Rana McKay Rafee Talukder Shilpa Gupta Adam Weiner Adam Kibel aurelius omlin Arnab Basu Arvin K. George, MD Arun Azad π³ππππ π²ππππ Ciara Conduit Dana-Farber Lank Center for Genitourinary Oncology Dan George Ali Khaki Mike Glover Daniel Petrylak D'Ann George Deborah Mukherji DrTylerStewart Emmanuel Antonarakis EAU Edu Platform UROONCO Elena Castro Edward Schaeffer Eric Jonasch Tamas Fazekas MD Jean Hoffman-Censits Brian Shuch, MD Miguel Sotelo Santhosh Ambika Russell Pachynski Scot Niglio MD Alfonso GΓ³mez de LiaΓ±o Sam S. Chang MD, MBA Joseph Vento Tom Powles drfrankiejs Katy Beckermann Albert Jang, MD Michiel van der Heijden Guru P. Sonpavde, MD Andrea Necchi 22/22 #TumorBoardTuesday
Take home points:
β
New SOC for 1L la/mUC β EV + Pembro with 53% β¬οΈ risk of death, nearly doubled mOS
β
Many questions unanswered to optimize EV + IO and subsequent lines of tx
β
Ongoing trials looking at peri-op EV + IO for MIBC
#TumorBoardTuesday Matt Galsky Amanda Nizam, MD Brian Rini, MD Petros Grivas Nick James Toni Choueiri, MD Rana McKay Rafee Talukder Shilpa Gupta Adam Weiner Adam Kibel aurelius omlin Arnab Basu Arvin K. George, MD Arun Azad π³ππππ π²ππππ Ciara Conduit Dana-Farber Lank Center for Genitourinary Oncology Dan George Ali Khaki Mike Glover Daniel Petrylak D'Ann George Deborah Mukherji DrTylerStewart Emmanuel Antonarakis EAU Edu Platform UROONCO Elena Castro Edward Schaeffer Eric Jonasch Tamas Fazekas MD Jean Hoffman-Censits Brian Shuch, MD Miguel Sotelo Santhosh Ambika Russell Pachynski Scot Niglio MD Alfonso GΓ³mez de LiaΓ±o Sam S. Chang MD, MBA Joseph Vento Tom Powles drfrankiejs Katy Beckermann Albert Jang, MD Michiel van der Heijden Guru P. Sonpavde, MD Andrea Necchi 21/22 #TumorBoardTuesday
β¨Remaining Questionsβ¨
π€Chemo + dual IO in mUCβ
β‘οΈNILE: Ph3 durva + tremelimumab + chemo
#TumorBoardTuesday Matt Galsky Amanda Nizam, MD Brian Rini, MD Petros Grivas Nick James Toni Choueiri, MD Rana McKay Rafee Talukder Shilpa Gupta Adam Weiner Adam Kibel aurelius omlin Arnab Basu Arvin K. George, MD Arun Azad π³ππππ π²ππππ Ciara Conduit Dana-Farber Lank Center for Genitourinary Oncology Dan George Ali Khaki Mike Glover Daniel Petrylak D'Ann George Deborah Mukherji DrTylerStewart Emmanuel Antonarakis EAU Edu Platform UROONCO Elena Castro Edward Schaeffer Eric Jonasch Tamas Fazekas MD Jean Hoffman-Censits Brian Shuch, MD Miguel Sotelo Santhosh Ambika Russell Pachynski Scot Niglio MD Alfonso GΓ³mez de LiaΓ±o Sam S. Chang MD, MBA Joseph Vento Tom Powles drfrankiejs Katy Beckermann Albert Jang, MD Michiel van der Heijden Guru P. Sonpavde, MD Andrea Necchi 20/22 #TumorBoardTuesday
β¨Remaining Qβ¨
π€Role for EV + IO in earlier stage Dzβ
β‘οΈEV-303/KN-905: Ph3 peri-op EV+Pembro in Cis-ineligible MIBC
β‘οΈEV-304/KN-B15: Ph3 peri-op EV+Pembro in Cis-eligible MIBC
β‘οΈVOLGA: Ph3 peri-op EV+durvalumab +/- tremelimumab in cis-ineligible MIBC
Jon Anker, MD, PhD #TumorBoardTuesday Amanda Nizam, MD Brian Rini, MD Petros Grivas Nick James Toni Choueiri, MD Rana McKay Rafee Talukder Shilpa Gupta Adam Weiner Adam Kibel aurelius omlin Arnab Basu Arvin K. George, MD Arun Azad π³ππππ π²ππππ Ciara Conduit Dana-Farber Lank Center for Genitourinary Oncology Dan George Ali Khaki Mike Glover Daniel Petrylak D'Ann George Deborah Mukherji DrTylerStewart Emmanuel Antonarakis EAU Edu Platform UROONCO Elena Castro Edward Schaeffer Eric Jonasch Tamas Fazekas MD Jean Hoffman-Censits Brian Shuch, MD Miguel Sotelo Santhosh Ambika Russell Pachynski Scot Niglio MD Alfonso GΓ³mez de LiaΓ±o Sam S. Chang MD, MBA Joseph Vento Tom Powles drfrankiejs Katy Beckermann Albert Jang, MD Michiel van der Heijden Guru P. Sonpavde, MD Andrea Necchi
Jon Anker, MD, PhD #TumorBoardTuesday Amanda Nizam, MD Brian Rini, MD Petros Grivas Nick James Toni Choueiri, MD Rana McKay Rafee Talukder Shilpa Gupta Adam Weiner Adam Kibel aurelius omlin Arnab Basu Arvin K. George, MD Arun Azad π³ππππ π²ππππ Ciara Conduit Dana-Farber Lank Center for Genitourinary Oncology Dan George Ali Khaki Mike Glover Daniel Petrylak D'Ann George Deborah Mukherji DrTylerStewart Emmanuel Antonarakis EAU Edu Platform UROONCO Elena Castro Edward Schaeffer Eric Jonasch Tamas Fazekas MD Jean Hoffman-Censits Brian Shuch, MD Miguel Sotelo Santhosh Ambika Russell Pachynski Scot Niglio MD Alfonso GΓ³mez de LiaΓ±o Sam S. Chang MD, MBA Joseph Vento Tom Powles drfrankiejs Katy Beckermann Albert Jang, MD Michiel van der Heijden Guru P. Sonpavde, MD Andrea Necchi
Jon Anker, MD, PhD #TumorBoardTuesday Amanda Nizam, MD Brian Rini, MD Petros Grivas Nick James Toni Choueiri, MD Rana McKay Rafee Talukder Shilpa Gupta Adam Weiner Adam Kibel aurelius omlin Arnab Basu Arvin K. George, MD Arun Azad π³ππππ π²ππππ Ciara Conduit Dana-Farber Lank Center for Genitourinary Oncology Dan George Ali Khaki Mike Glover Daniel Petrylak D'Ann George Deborah Mukherji DrTylerStewart Emmanuel Antonarakis EAU Edu Platform UROONCO Elena Castro Edward Schaeffer Eric Jonasch Tamas Fazekas MD Jean Hoffman-Censits Brian Shuch, MD Miguel Sotelo Santhosh Ambika Russell Pachynski Scot Niglio MD Alfonso GΓ³mez de LiaΓ±o Sam S. Chang MD, MBA Joseph Vento Tom Powles drfrankiejs Katy Beckermann Albert Jang, MD Michiel van der Heijden Guru P. Sonpavde, MD Andrea Necchi
Jon Anker, MD, PhD #TumorBoardTuesday Amanda Nizam, MD Brian Rini, MD Petros Grivas Nick James Toni Choueiri, MD Rana McKay Rafee Talukder Shilpa Gupta Adam Weiner Adam Kibel aurelius omlin Arnab Basu Arvin K. George, MD Arun Azad π³ππππ π²ππππ Ciara Conduit Dana-Farber Lank Center for Genitourinary Oncology Dan George Ali Khaki Mike Glover Daniel Petrylak D'Ann George Deborah Mukherji DrTylerStewart Emmanuel Antonarakis EAU Edu Platform UROONCO Elena Castro Edward Schaeffer Eric Jonasch Tamas Fazekas MD Jean Hoffman-Censits Brian Shuch, MD Miguel Sotelo Santhosh Ambika Russell Pachynski Scot Niglio MD Alfonso GΓ³mez de LiaΓ±o Sam S. Chang MD, MBA Joseph Vento Tom Powles drfrankiejs Katy Beckermann Albert Jang, MD Michiel van der Heijden Guru P. Sonpavde, MD Andrea Necchi
Jon Anker, MD, PhD #TumorBoardTuesday Amanda Nizam, MD Brian Rini, MD Petros Grivas Nick James Toni Choueiri, MD Rana McKay Rafee Talukder Shilpa Gupta Adam Weiner Adam Kibel aurelius omlin Arnab Basu Arvin K. George, MD Arun Azad π³ππππ π²ππππ Ciara Conduit Dana-Farber Lank Center for Genitourinary Oncology Dan George Ali Khaki Mike Glover Daniel Petrylak D'Ann George Deborah Mukherji DrTylerStewart Emmanuel Antonarakis EAU Edu Platform UROONCO Elena Castro Edward Schaeffer Eric Jonasch Tamas Fazekas MD Jean Hoffman-Censits Brian Shuch, MD Miguel Sotelo Santhosh Ambika Russell Pachynski Scot Niglio MD Alfonso GΓ³mez de LiaΓ±o Sam S. Chang MD, MBA Joseph Vento Tom Powles drfrankiejs Katy Beckermann Albert Jang, MD Michiel van der Heijden Guru P. Sonpavde, MD Andrea Necchi
Jon Anker, MD, PhD #TumorBoardTuesday Amanda Nizam, MD Brian Rini, MD Petros Grivas Nick James Toni Choueiri, MD Rana McKay Rafee Talukder Shilpa Gupta Adam Weiner Adam Kibel aurelius omlin Arnab Basu Arvin K. George, MD Arun Azad π³ππππ π²ππππ Ciara Conduit Dana-Farber Lank Center for Genitourinary Oncology Dan George Ali Khaki Mike Glover Daniel Petrylak D'Ann George Deborah Mukherji DrTylerStewart Emmanuel Antonarakis EAU Edu Platform UROONCO Elena Castro Edward Schaeffer Eric Jonasch Tamas Fazekas MD Jean Hoffman-Censits Brian Shuch, MD Miguel Sotelo Santhosh Ambika Russell Pachynski Scot Niglio MD Alfonso GΓ³mez de LiaΓ±o Sam S. Chang MD, MBA Joseph Vento Tom Powles drfrankiejs Katy Beckermann Albert Jang, MD Michiel van der Heijden Guru P. Sonpavde, MD Andrea Necchi HER2 is an interesting target in UC.
#TumorBoardTuesday Matt Galsky Amanda Nizam, MD Brian Rini, MD Petros Grivas Nick James Toni Choueiri, MD Rana McKay Rafee Talukder Shilpa Gupta Adam Weiner Adam Kibel aurelius omlin Arnab Basu Arvin K. George, MD Arun Azad π³ππππ π²ππππ Ciara Conduit Dana-Farber Lank Center for Genitourinary Oncology Dan George Ali Khaki Mike Glover Daniel Petrylak D'Ann George Deborah Mukherji DrTylerStewart Emmanuel Antonarakis EAU Edu Platform UROONCO Elena Castro Edward Schaeffer Eric Jonasch Tamas Fazekas MD Jean Hoffman-Censits Brian Shuch, MD Miguel Sotelo Santhosh Ambika Russell Pachynski Scot Niglio MD Alfonso GΓ³mez de LiaΓ±o Sam S. Chang MD, MBA Joseph Vento Tom Powles drfrankiejs Katy Beckermann Albert Jang, MD Michiel van der Heijden Guru P. Sonpavde, MD Andrea Necchi 19/22 #TumorBoardTuesday
β‘οΈOther remaining lines of tx:
πSacituzumab govitecan, erdafitinib (if +FGFR 2/3), clinical trial
π€Ok to give ADC with same payload in later lineβ πDisitamab vedotin (MMAE) + IOπ‘prelim results promising for HER2+ UC
#TumorBoardTuesday Matt Galsky Amanda Nizam, MD Brian Rini, MD Petros Grivas Nick James Toni Choueiri, MD Rana McKay Rafee Talukder Shilpa Gupta Adam Weiner Adam Kibel aurelius omlin Arnab Basu Arvin K. George, MD Arun Azad π³ππππ π²ππππ Ciara Conduit Dana-Farber Lank Center for Genitourinary Oncology Dan George Ali Khaki Mike Glover Daniel Petrylak D'Ann George Deborah Mukherji DrTylerStewart Emmanuel Antonarakis EAU Edu Platform UROONCO Elena Castro Edward Schaeffer Eric Jonasch Tamas Fazekas MD Jean Hoffman-Censits Brian Shuch, MD Miguel Sotelo Santhosh Ambika Russell Pachynski Scot Niglio MD Alfonso GΓ³mez de LiaΓ±o Sam S. Chang MD, MBA Joseph Vento Tom Powles drfrankiejs Katy Beckermann Albert Jang, MD Michiel van der Heijden Guru P. Sonpavde, MD Andrea Necchi 18/22 #TumorBoardTuesday
β¨Remaining Questionsβ¨
β‘οΈPotential role for 2L gem/cis + nivo despite progression on pembro unknown
π€What if pt had progressed off pembroβ
#TumorBoardTuesday Matt Galsky Amanda Nizam, MD Brian Rini, MD Petros Grivas Nick James Toni Choueiri, MD Rana McKay Rafee Talukder Shilpa Gupta Adam Weiner Adam Kibel aurelius omlin Arnab Basu Arvin K. George, MD Arun Azad π³ππππ π²ππππ Ciara Conduit Dana-Farber Lank Center for Genitourinary Oncology Dan George Ali Khaki Mike Glover Daniel Petrylak D'Ann George Deborah Mukherji DrTylerStewart Emmanuel Antonarakis EAU Edu Platform UROONCO Elena Castro Edward Schaeffer Eric Jonasch Tamas Fazekas MD Jean Hoffman-Censits Brian Shuch, MD Miguel Sotelo Santhosh Ambika Russell Pachynski Scot Niglio MD Alfonso GΓ³mez de LiaΓ±o Sam S. Chang MD, MBA Joseph Vento Tom Powles drfrankiejs Katy Beckermann Albert Jang, MD Michiel van der Heijden Guru P. Sonpavde, MD Andrea Necchi 17/22 #TumorBoardTuesday
β¨Remaining Questionsβ¨
π€What should be 2L after EV + pembroβ
β‘οΈChemo (gem+cis/carbo or ddMVAC)β
πIn EV-302, most Pts needing 2β£L Tx after EV + pembro received platinum-based chemo
Johnathan Ebben MD, PhD Mike Pishvaian Jon Anker, MD, PhD #TumorBoardTuesday Amanda Nizam, MD Brian Rini, MD Petros Grivas Nick James Toni Choueiri, MD Rana McKay Rafee Talukder Shilpa Gupta Adam Weiner Adam Kibel aurelius omlin Arnab Basu Arvin K. George, MD Arun Azad π³ππππ π²ππππ Ciara Conduit Dana-Farber Lank Center for Genitourinary Oncology Dan George Ali Khaki Mike Glover Daniel Petrylak D'Ann George Deborah Mukherji DrTylerStewart Emmanuel Antonarakis EAU Edu Platform UROONCO Elena Castro Edward Schaeffer Eric Jonasch Tamas Fazekas MD Jean Hoffman-Censits Brian Shuch, MD Miguel Sotelo Santhosh Ambika Russell Pachynski Scot Niglio MD Alfonso GΓ³mez de LiaΓ±o Sam S. Chang MD, MBA Joseph Vento Tom Powles drfrankiejs Katy Beckermann Albert Jang, MD Yu-Wei Chen, MD, MS Christopher Hoimes Jonathan Rosenberg MD
Johnathan Ebben MD, PhD Mike Pishvaian Jon Anker, MD, PhD #TumorBoardTuesday Amanda Nizam, MD Brian Rini, MD Petros Grivas Nick James Toni Choueiri, MD Rana McKay Rafee Talukder Shilpa Gupta Adam Weiner Adam Kibel aurelius omlin Arnab Basu Arvin K. George, MD Arun Azad π³ππππ π²ππππ Ciara Conduit Dana-Farber Lank Center for Genitourinary Oncology Dan George Ali Khaki Mike Glover Daniel Petrylak D'Ann George Deborah Mukherji DrTylerStewart Emmanuel Antonarakis EAU Edu Platform UROONCO Elena Castro Edward Schaeffer Eric Jonasch Tamas Fazekas MD Jean Hoffman-Censits Brian Shuch, MD Miguel Sotelo Santhosh Ambika Russell Pachynski Scot Niglio MD Alfonso GΓ³mez de LiaΓ±o Sam S. Chang MD, MBA Joseph Vento Tom Powles drfrankiejs Katy Beckermann Albert Jang, MD Yu-Wei Chen, MD, MS Christopher Hoimes Jonathan Rosenberg MD No, it doesnt consistently. THere are several potential reasons for this.
Johnathan Ebben MD, PhD Mike Pishvaian Jon Anker, MD, PhD #TumorBoardTuesday Matt Galsky Amanda Nizam, MD Brian Rini, MD Petros Grivas Nick James Toni Choueiri, MD Rana McKay Rafee Talukder Shilpa Gupta Adam Weiner Adam Kibel aurelius omlin Arnab Basu Arvin K. George, MD Arun Azad π³ππππ π²ππππ Ciara Conduit Dana-Farber Lank Center for Genitourinary Oncology Dan George Ali Khaki Mike Glover Daniel Petrylak D'Ann George Deborah Mukherji DrTylerStewart Emmanuel Antonarakis EAU Edu Platform UROONCO Elena Castro Edward Schaeffer Eric Jonasch Tamas Fazekas MD Jean Hoffman-Censits Brian Shuch, MD Miguel Sotelo Santhosh Ambika Russell Pachynski Scot Niglio MD Alfonso GΓ³mez de LiaΓ±o Sam S. Chang MD, MBA Joseph Vento Tom Powles drfrankiejs Katy Beckermann Albert Jang, MD Yu-Wei Chen, MD, MS Christopher Hoimes π€―